Directed new share issue in Xbrane Biopharma AB (SE) — SEK 20 million

Carnegie acted as financial adviser in the directed new share issue of 655,738 new shares at a subscription price of SEK 30.50 per share. Xbrane is a commercial phase Swedish biopharmaceutical company specialised in biosimilars and long acting injectables. June 2017.